Women’s health pharma company Theramex and ObsEva, a biopharma company developing and commercializing novel therapies for women’s health have entered into a licensing agreement to commercialize and launch Linzagolix, an oral GnRH antagonist. The launch will be for global markets outside of the U.S., Canada, and Asia. Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids. Linzagolix is also…
